De novo classification of ocular pressure pump tops recent glaucoma headlines
Click Here to Manage Email Alerts
Healio’s recent stories in glaucoma include the de novo classification of an ocular pressure adjusting pump and promising results with timolol microdrops to lower IOP.
Check out these glaucoma articles and more below.
Image: Adobe Stock
FDA grants de novo classification to Fysx ocular pressure adjusting pump
The FDA granted de novo classification to the Fysx ocular pressure adjusting pump for patients with normal-tension glaucoma or open-angle glaucoma with IOP of 21 mm Hg or less, according to a press release from Balance Ophthalmics. Read more.
Timolol microdrops appear as effective as conventional drops in lowering IOP
Timolol maleate 0.5% microdrops delivered with the Nanodropper Adaptor met three noninferiority endpoints in lowering IOP compared with conventional timolol drops. Read more.
‘Look at whole picture’ to detect glaucoma progression
To detect glaucoma progression, physicians need to look at all available data and imaging, according to a presentation at Real World Ophthalmology. Read more.
Sustained-release bimatoprost implant shows safety, efficacy in early study
A sustained-release bimatoprost drug delivery platform shows promise in the treatment of ocular hypertension and open-angle glaucoma, according to a poster at the American Society of Cataract and Refractive Surgery meeting. Read more.
Alcon acquires Belkin Vision, direct selective laser trabeculoplasty device
Alcon completed the acquisition of Belkin Vision, including its direct selective laser trabeculoplasty technology. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts